Oxford BioDynamics EpiSwitch Prostate Screening (PSE) Test
Oxford BioDynamics said this week that its EpiSwitch Prostate Screening (PSE) test has been validated in its CLIA-certified laboratory in Frederick, Maryland, and the assay has been launched in the US for clinical customers. The PSE test is run alongside a standard PSA test to predict the presence or absence of prostate cancer. Oxford BioDynamics reports a specificity of 97 percent and sensitivity of 86 for the test, yielding a 93 percent positive predictive value and a 95 percent negative predictive value. Testing results will be available in five days after a blood sample is received, the company said.